BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

BMY upcoming catalysts

Bristol-Myers Squibb: 5 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 19 readout(s) and 6 FDA event(s). Subscribe to BMY (.ics).

Drugs: Nivolumab, Deucravacitinib, Dexamethasone, Ipilimumab, Cisplatin, KarXT, BMS-986435, BMS-986446, BMS-986470, Famotidine, Pantoprazole, Carboplatin, Paclitaxel, Pemetrexed, Repotrectinib, Crizotinib, Tazemetostat, Trametinib, Mezigdomide, Carfilzomib, Bevacizumab, Sorafenib, lenvatinib, Elotuzumab, Lenalidomide, Bortezomib, Pomalidomide, Gemcitabine

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-12-14 est.P2Bristol-Myers Squibb BMYNCT06122779 Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF)Heart Failureactive not recruiting227
2026-12-17 est.P2Bristol-Myers Squibb BMYNCT06268886 Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's DiseaseAlzheimer Disease, Early Onsetactive not recruiting310
2027-01-06 est.P1/P2Bristol-Myers Squibb BMYNCT06481306 A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell DiseaseAnemia, Sickle Cell; Healthy Volunteersrecruiting224
2027-02-05 est.P2Bristol-Myers Squibb BMYNCT06946797 A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously UnNon-Small Cell Lung Canceractive not recruiting76
2027-02-16 est.P3Bristol-Myers Squibb BMYNCT06140836 A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small CelCarcinoma, Non-Small-Cell Lungactive not recruiting190

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-09-30FDA approvalapprovedBRISTOL BMYCAMZYOSApproved 2026-09-30: CAMZYOS (NDA214998 SUPPL13)
2026-08-13FDA approvalapprovedBRISTOL MYERS SQUIBB BMYZENBEXUSApproved 2026-08-13: ZENBEXUS (NDA221075 ORIG1)
2026-04-09FDA approvalapprovedBRISTOL BMYONUREGApproved 2026-04-09: ONUREG (NDA214120 SUPPL3)
2026-03-20FDA approvalapprovedBRISTOL MYERS SQUIBB BMYOPDIVOApproved 2026-03-20: OPDIVO (BLA125554 SUPPL135)
2026-03-06FDA approvalapprovedBRISTOL BMYSOTYKTUApproved 2026-03-06: SOTYKTU (NDA214958 SUPPL2)
2025-11-24FDA approvalapprovedBRISTOL-MYERS SQUIBB BMYOPDIVO QVANTIGApproved 2025-11-24: OPDIVO QVANTIG (BLA761381 SUPPL5)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-11-18 est.P3Bristol-Myers Squibb BMYNCT05946941 A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's SyndromeSjögren's Syndromeactive not recruiting774
2026-11-02 est.P3Bristol-Myers Squibb BMYNCT06951711 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder (BALSAM-2)Bipolar Disorder Type I With Mania or Mania With Mixed Featuresrecruiting274
2026-11-01 est.P3Bristol-Myers Squibb BMYNCT06951698 A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I DisorderBipolar-I Disorder With Mania or Mania With Mixed Featuresrecruiting274
2026-10-19 est.P3Bristol-Myers Squibb BMYNCT05620407 A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus ErythematosusSystemic Lupus Erythematosusactive not recruiting513
2026-10-19 est.P3Bristol-Myers Squibb BMYNCT05617677 A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Systemic Lupus Erythematosusactive not recruiting516
2026-10-12 est.P1/P2Bristol-Myers Squibb BMYNCT05372354 A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed or RefractMultiple Myelomarecruiting260
2026-10-06 est.P3Bristol-Myers Squibb BMYNCT06003426 A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisIdiopathic Pulmonary Fibrosisactive not recruiting1255
2026-09-30 est.P1/P2Bristol-Myers Squibb BMYNCT05888831 A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid TumorsAdvanced Solid Tumorsactive not recruiting100
2026-09-28 est.P3Bristol-Myers Squibb BMYNCT05552976 A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With RelapsRelapsed or Refractory Multiple Myelomaactive not recruiting606
2026-09-05 est.P1/P2Bristol-Myers Squibb BMYNCT06730750 A Study of BMS-986490 With or Without Bevacizumab in Advanced Solid TumorsAdvanced Solid Tumorsactive not recruiting360
2026-08-11P1/P2Bristol-Myers Squibb BMYNCT06035497 A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas iRelapsed or Refractory T-cell Lymphomasactive not recruiting83
2026-07-21P3Bristol-Myers Squibb BMYNCT04036435 Long-Term Study That Measures the Safety and Efficacy of Deucravacitinib (BMS-986165) in Participants With PsoriasisPsoriasiscompleted1466
2026-07-09P3Bristol-Myers Squibb BMYNCT04039607 A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaHepatocellular Carcinomacompleted732
2026-05-27P3Bristol-Myers Squibb BMYNCT03383458 A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationHepatocellular Carcinoma; Liver Canceractive not recruiting545
2026-02-23P2Bristol-Myers Squibb BMYNCT02719613 Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating ElotuzumabMultiple Myelomacompleted67
2026-02-16P3Bristol-Myers Squibb BMYNCT03661320 A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With NivolumabUrinary Bladder Neoplasms; Muscle-Invasive Bladder Cancercompleted855
2026-01-16P2/P3Bristol-Myers Squibb BMYNCT03723655 A Long-Term Safety Extension Study of Mavacamten in Adults Who Have Completed MAVERICK-HCM or EXPLORER-HCMHypertrophic Cardiomyopathy; Obstructive Hypertrophic Cardiomyopathy; Non-obstructive Hypertrophic Ccompleted314
2025-12-03P1/P2Bristol-Myers Squibb BMYNCT05255601 A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Lymphoma, Non-Hodgkin; Hodgkin Diseaseterminated5
2025-11-25P3Bristol-Myers Squibb BMYNCT06253221 A Study to Evaluate Mavacamten in Adolescents With Symptomatic Obstructive Hypertrophic CardiomyopathyCardiomyopathy, Hypertrophicactive not recruiting44

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.